hotspot -WSS

hotspot

author：hotspot 2025-09-06 02:14:08 - browse：955

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Indian pharmaceutical industry in denial over drug

WSS

Driven by the pandemic, applicants flood public health schools

Affordable Connectivity Program vital to health care, experts say

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

How I helped Pfizer think through the ethics of Viagra

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

DeSantis talks Trump, trans issues and 'what wokeness is'

leisure time

hotspot

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

EF3 tornado rips through North Carolina amid extreme weather nationwide

BioMarin wins approval for gene therapy to treat hemophilia A

Pharma showers House GOP doctor with campaign cash

Medicare details structure of new drug price negotiation program

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

After affirmative action ruling, medical educators look to 'holistic review'

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Novavax promises a turnaround & Lilly roils the obesity market

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

focus

Hospitals struggle to profit from CAR

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

H.R. 3 is the wrong path to lower drug costs

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Driven by the pandemic, applicants flood public health schools

I learned firsthand about improving diversity in clinical trials

entertainment

leisure time

leisure time

Wikipedia